Valuation: VISEN Pharmaceuticals

Market Cap 179.81Cr 208.26Cr 27Cr 23Cr 22Cr 20Cr 37Cr 2.56TCr 38Cr 257.57Cr 100.63Cr 1.26TCr 100Cr 98Cr 4.35TCr P/E 2026 *
-17.5x
P/E 2027 * -29.4x
Enterprise Value 153.58Cr 177.88Cr 23Cr 20Cr 19Cr 17Cr 32Cr 2.18TCr 32Cr 220Cr 86Cr 1.07TCr 85Cr 83Cr 3.71TCr EV / Sales 2026 *
22.7x
EV / Sales 2027 * 4.02x
Free-Float
26.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-0.52%
Current month-4.40%
1 month-3.58%
3 months-22.42%
6 months-49.36%
Current year-41.77%
1 week 18.5
Extreme 18.5
20.18
1 month 18.5
Extreme 18.5
26.96
Current year 18.5
Extreme 18.5
43.3
1 year 18.5
Extreme 18.5
52.9
3 years 18.5
Extreme 18.5
69.15
5 years 18.5
Extreme 18.5
69.15
10 years 18.5
Extreme 18.5
69.15
Manager TitleAgeSince
Chief Executive Officer 60 07/11/2018
Director of Finance/CFO 42 13/10/2025
Chief Tech/Sci/R&D Officer 54 01/04/2020
Director TitleAgeSince
Director/Board Member 53 01/04/2021
Director/Board Member 60 01/04/2021
Director/Board Member 58 27/08/2025
Date Insider Type Main position Quantity % Market Cap.
01/01/26 Other

Chief Executive Officer

1,08,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-0.52%-61.02% - 27Cr
+1.07%-3.49%-3.35%+10.44% 4.69TCr
+0.25%+1.65%+399.22%+634.87% 4.02TCr
-0.27%+4.45%+11.81%+65.64% 3.62TCr
+0.35%+0.87%+4.46%-10.16% 3.47TCr
+3.14%+1.02%+4.76%+40.92% 2.79TCr
-0.73%+11.84%+34.39%+134.36% 1.68TCr
+0.47%-2.74% - - 1.67TCr
+0.42%-5.52%-3.43%+9.03% 1.31TCr
-2.68%-2.49%-11.36%-33.61% 1.27TCr
Average +0.12%+0.70%+41.72%+106.44% 2.46TCr
Weighted average by Cap. +0.48%+0.91%+74.26%+136.27%

Financials

2026 *2027 *
Net sales 6.77Cr 7.85Cr 1Cr 87.86L 81.71L 74.98L 1.41Cr 96Cr 1.43Cr 9.7Cr 3.79Cr 47Cr 3.76Cr 3.67Cr 163.76Cr 45Cr 52Cr 6.61Cr 5.8Cr 5.4Cr 4.95Cr 9.31Cr 636.33Cr 9.45Cr 64Cr 25Cr 312.84Cr 25Cr 24Cr 1.08TCr
Net income -9.9Cr -11Cr -1.46Cr -1.28Cr -1.19Cr -1.1Cr -2.06Cr -140.8Cr -2.09Cr -14Cr -5.54Cr -69Cr -5.49Cr -5.37Cr -239.34Cr -5.8Cr -6.72Cr -85.66L -75.23L -69.97L -64.2L -1.21Cr -82Cr -1.22Cr -8.31Cr -3.25Cr -41Cr -3.22Cr -3.15Cr -140.22Cr
Net Debt -26Cr -30Cr -3.87Cr -3.4Cr -3.16Cr -2.9Cr -5.46Cr -373.08Cr -5.54Cr -38Cr -15Cr -183.42Cr -15Cr -14Cr -634.17Cr 5L 6L 71.79T 63.05T 58.64T 53.81T 1L 69.13L 1L 7L 3L 33.99L 3L 3L 1.18Cr
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
82
Date Price Change Volume
24/26/24 HK$19.10 -0.83% 15,100
23/26/23 HK$19.26 +1.80% 6,100
22/26/22 HK$18.92 +0.11% 10,500
21/26/21 HK$18.90 0.00% 11,100
20/26/20 HK$18.90 -1.56% 7,600
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16.49CNY
Average target price
44.50CNY
Spread / Average Target
+169.82%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2561 Stock